CR BOYA-BIO Stock Code: 300294 Stock Abbreviation: Boya Bio Announcement No.: 2026-012 China Resources Boya Bio-Pharmaceutical Group Co., Ltd. Announcement on the Estimated Annual Limit of Routine Related Transactions with Related Parties for 2026 The Company and the Board of Directors guarantee the authenticity, accuracy, and completeness of the information disclosed in this announcement and are not aware of any false records, misleading statements, or material omissions. I. Overview of Related Transactions In accordance with the "Company Law of the People's Republic of China," the "Shenzhen Stock Exchange GEM Stock Listing Rules" (hereinafter referred to as the "GEM Listing Rules"), and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 2 - Standardized Operation of GEM Listed Companies," China Resources Boya Bio-Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or "CR BOYA-BIO") considers China Resources Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as "CR Pharma Holdings"), its controlling shareholder, and its related parties as related parties of the Company. Transactions between the Company and CR Pharma Holdings and its related parties constitute related party transactions. The Company estimates the annual limit of routine related transactions with related parties for 2026 as follows: (I) 2025 Related Transactions
- 2025 Routine Related Transactions Based on the contracts, distribution agreements, and other transaction documents signed by the Company and its holding subsidiaries with CR Pharma Holdings and its related parties, the transaction situation between the Company and CR Pharma Holdings and its related parties in 2025 is as follows: | Related Transaction Category | Company/Holding Subsidiary | Pricing Principle | 2026 Projected Amount | 2025 Actual Amount | 2025 Projected Amount | 2025 Actual vs. Projected Difference | Unit: RMB Ten Thousand | |---|---|---|---|---|---|---|---| | Sales of Products to China Resources Pharmaceutical Holdings and its Related Parties | CR BOYA-BIO | Market-based pricing method | 25,090.00 | 21,247.45 | 23,940.00 | -2,692.55 | | | Nanjing Xinbai Pharmaceutical Co., Ltd. | | 1,270.00 | 1,215.53 | 1,280.00 | -64.47 | | | Jiangxi Boya Xinhe Pharmaceutical Co., Ltd. | | - | 46.77 | 110.00 | -63.22 | | | Green Cross (China) Biopharmaceutical Co., Ltd. | | 4,400.00 | 3,661.80 | 2,170.00 | 1,491.80 | | | Anhui Glinke Pharmaceutical Sales Co., Ltd. | | 450.00 | 372.99 | 910.00 | -537.01 | | Total | | | 31,210.00 | 26,544.54 | 28,410.00 | -1,865.46 | | | CR BOYA-BIO | | 8,273.00 | 5,772.75 | 9,570.00 | -3,797.25 | | | Nanjing Xinbai Pharmaceutical Co., Ltd. | | 1,049.90 | 1,698.98 | 1,360.00 | 338.98 | | Purchase of Products from China Resources Pharmaceutical Holdings and its Related Parties | Green Cross (China) Biopharmaceutical Co., Ltd. | Market-based pricing method | 1,761.00 | 624.39 | 182.00 | 442.39 | | | Anhui Glinke Pharmaceutical Sales Co., Ltd. | | 406.00 | 13.35 | 60.00 | -46.65 | | | Jiangxi Boya Xinhe Pharmaceutical Co., Ltd. | | - | 5.39 | 22.00 | -16.61 | | Subtotal of Plasma Collection Stations | | | 735.50 | 721.39 | 1,200.00 | -478.61 | | Total | | | 12,225.40 | 8,836.25 | 12,394.00 | -3,557.75 | | Grand Total | | | 43,435.40 | 35,380.79 | 40,804.00 | -5,423.21 | The actual amount of routine related party transactions executed by the Company with the above related parties in 2025 was RMB 35,380.79 million, which did not exceed the projected amount for 2025. The independent directors reviewed this matter and issued a clear opinion.
- 2025 Other Related Transactions On July 17, 2025, the Company convened the 14th meeting of the 8th Board of Directors and the 11th meeting of the 8th Supervisory Board. The fund has a scale of RMB 1 billion, and Shenzhen CR Capital Equity Investment Co., Ltd. is the fund manager. The Company, as a limited partner, has subscribed for a total capital contribution of RMB 60 million with its own funds, holding a 6% equity interest in the fund and bearing limited liability within the amount of its subscribed capital contribution. (II) Projected Routine Related Transactions for 2026 Based on daily operating needs, the Company projects that its routine related transactions with CR Pharma Holdings and its related parties in 2026 will not exceed RMB 43,435.40 million. The basic situation is as follows: | Related Transaction Category | Company/Holding Sub